5000872026-08-285000872026-08-282026-08-285000872026-08-282026-08-28RestructuringEntityDomain15000872026-08-28RestructuringEntityDomain15000872026-08-282026-08-28RestructuringEntityDomain25000872026-08-28RestructuringEntityDomain2xbrli:purexbrli:shares500087Cipla LimitedCIPLANOTLISTEDINE059A01026NewOther Restructuringfalse2026-08-2719:43:002026-08-28Aspergen LimitedSubsidiary000056000015600001000056000015600001Aspergen Inc.Step Down Subsidiary000010011001000010011001Aspergen Limited, India, a 60:40 joint venture between the Company and Kemwell Biopharma Private Limited, has acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary of the Company, from Cipla (EU) Limited (holding 60% stake), a wholly owned subsidiary of the Company, and Kemwell Biopharma UK Limited (holding 40% stake). Consequently, Aspergen Inc., USA, has become a wholly owned subsidiary of Aspergen Limited, India. There is no change in the Company's economic interest in Aspergen Inc., USA, pursuant to the aforesaid restructuring. The said restructuring has been undertaken with a view to rationalise and simplify the group structure.-The said restructuring has been undertaken with a view to rationalise and simplify the group structure.falsePre-restructuring shareholding structure: (A) Aspergen Limited, India: (i) Cipla Limited: 60%; (ii) Kemwell Biopharma Private Limited: 40%. (B) Aspergen Inc., USA: (i) Cipla (EU) Limited (wholly owned subsidiary of Cipla Limited): 60%; (ii) Kemwell Biopharma UK Limited: 40%. Post-restructuring shareholding structure: (A) Aspergen Limited, India: (i) Cipla Limited: 60%; (ii) Kemwell Biopharma Private Limited: 40%. (B) Aspergen Inc., USA: Aspergen Limited, India: 100%.